252 related articles for article (PubMed ID: 27882195)
1. Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload.
Tiberghien AC; Levy JN; Masterson LA; Patel NV; Adams LR; Corbett S; Williams DG; Hartley JA; Howard PW
ACS Med Chem Lett; 2016 Nov; 7(11):983-987. PubMed ID: 27882195
[TBL] [Abstract][Full Text] [Related]
2. Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy.
Hartley JA
Expert Opin Biol Ther; 2021 Jul; 21(7):931-943. PubMed ID: 32543981
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study.
Blackhall F; Jao K; Greillier L; Cho BC; Penkov K; Reguart N; Majem M; Nackaerts K; Syrigos K; Hansen K; Schuette W; Cetnar J; Cappuzzo F; Okamoto I; Erman M; Langer SW; Kato T; Groen H; Sun Z; Luo Y; Tanwani P; Caffrey L; Komarnitsky P; Reinmuth N
J Thorac Oncol; 2021 Sep; 16(9):1547-1558. PubMed ID: 33607312
[TBL] [Abstract][Full Text] [Related]
4. Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine.
Hartley JA; Flynn MJ; Bingham JP; Corbett S; Reinert H; Tiberghien A; Masterson LA; Antonow D; Adams L; Chowdhury S; Williams DG; Mao S; Harper J; Havenith CEG; Zammarchi F; Chivers S; van Berkel PH; Howard PW
Sci Rep; 2018 Jul; 8(1):10479. PubMed ID: 29992976
[TBL] [Abstract][Full Text] [Related]
5. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
Rudin CM; Pietanza MC; Bauer TM; Ready N; Morgensztern D; Glisson BS; Byers LA; Johnson ML; Burris HA; Robert F; Han TH; Bheddah S; Theiss N; Watson S; Mathur D; Vennapusa B; Zayed H; Lally S; Strickland DK; Govindan R; Dylla SJ; Peng SL; Spigel DR;
Lancet Oncol; 2017 Jan; 18(1):42-51. PubMed ID: 27932068
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the DLL3-targeting antibody-drug conjugate rovalpituzumab tesirine in preclinical models of neuroblastoma.
Krytska K; Casey CE; Pogoriler J; Martinez D; Rathi KS; Farrel A; Berko ER; Tsang M; Sano RR; Kendsersky N; Erickson SW; Teicher BA; Isse K; Saunders L; Smith MA; Maris JM; Mossé YP
Cancer Res Commun; 2022 Jul; 2(7):616-623. PubMed ID: 36381237
[TBL] [Abstract][Full Text] [Related]
7. Targeting CD19-positive lymphomas with the antibody-drug conjugate loncastuximab tesirine: preclinical evidence as single agent and in combination therapy.
Tarantelli C; Wald D; Munz N; Spriano F; Bruscaggin A; Cannas E; Cascione L; Gaudio E; Arribas AJ; Manjappa S; Golino G; Scalise L; Cacciapuoti MT; Zucca E; Stathis A; Inghirami G; Van Berkel PH; Rossi D; Caimi PF; Zammarchi F; Bertoni F
Haematologica; 2024 May; ():. PubMed ID: 38721745
[TBL] [Abstract][Full Text] [Related]
8. Design and Synthesis of Isoquinolidinobenzodiazepine Dimers, a Novel Class of Antibody-Drug Conjugate Payload.
Smith SW; Jammalamadaka V; Borkin D; Zhu J; Degrado SJ; Lu J; Huang J; Jiang YP; Jain N; Junutula JR
ACS Med Chem Lett; 2018 Jan; 9(1):56-60. PubMed ID: 29348812
[TBL] [Abstract][Full Text] [Related]
9. Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer.
Udagawa H; Akamatsu H; Tanaka K; Takeda M; Kanda S; Kirita K; Teraoka S; Nakagawa K; Fujiwara Y; Yasuda I; Okubo S; Shintani M; Kosloski MP; Scripture C; Tamura T; Okamoto I
Lung Cancer; 2019 Sep; 135():145-150. PubMed ID: 31446987
[TBL] [Abstract][Full Text] [Related]
10. Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion.
Dimasi N; Fleming R; Zhong H; Bezabeh B; Kinneer K; Christie RJ; Fazenbaker C; Wu H; Gao C
Mol Pharm; 2017 May; 14(5):1501-1516. PubMed ID: 28245132
[TBL] [Abstract][Full Text] [Related]
11. Rovalpituzumab tesirine resistance: analysis of a corresponding small cell lung cancer and circulating tumor cell line pair.
Rath B; Plangger A; Krenbek D; Hochmair M; Stickler S; Tretter V; Hamilton G
Anticancer Drugs; 2022 Mar; 33(3):300-307. PubMed ID: 34924498
[TBL] [Abstract][Full Text] [Related]
12. Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study.
Johnson ML; Zvirbule Z; Laktionov K; Helland A; Cho BC; Gutierrez V; Colinet B; Lena H; Wolf M; Gottfried M; Okamoto I; van der Leest C; Rich P; Hung JY; Appenzeller C; Sun Z; Maag D; Luo Y; Nickner C; Vajikova A; Komarnitsky P; Bar J
J Thorac Oncol; 2021 Sep; 16(9):1570-1581. PubMed ID: 33823285
[TBL] [Abstract][Full Text] [Related]
13. A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC.
Hann CL; Burns TF; Dowlati A; Morgensztern D; Ward PJ; Koch MM; Chen C; Ludwig C; Patel M; Nimeiri H; Komarnitsky P; Camidge DR
J Thorac Oncol; 2021 Sep; 16(9):1582-1588. PubMed ID: 34242790
[TBL] [Abstract][Full Text] [Related]
14. Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer.
White JB; Fleming R; Masterson L; Ruddle BT; Zhong H; Fazenbaker C; Strout P; Rosenthal K; Reed M; Muniz-Medina V; Howard P; Dixit R; Wu H; Hinrichs MJ; Gao C; Dimasi N
MAbs; 2019 Apr; 11(3):500-515. PubMed ID: 30835621
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Pyrrolobenzodiazepine Dimer Bis-imine versus Mono-imine: DNA Interstrand Cross-linking, Cytotoxicity, Antibody-Drug Conjugate Efficacy and Toxicity.
Tiberghien AC; Vijayakrishnan B; Esfandiari A; Ahmed M; Pardo R; Bingham J; Adams L; Santos K; Kang GD; Pugh KM; Afif-Rider S; Vashisht K; Haque K; Tammali R; Rosfjord E; Savoca A; Hartley JA; Howard PW
Mol Cancer Ther; 2023 Feb; 22(2):254-263. PubMed ID: 36722141
[TBL] [Abstract][Full Text] [Related]
16. Loncastuximab tesirine for treatment of relapsed or refractory diffuse large B cell lymphoma.
Goparaju K; Caimi PF
Expert Opin Biol Ther; 2021 Nov; 21(11):1373-1381. PubMed ID: 34505550
[TBL] [Abstract][Full Text] [Related]
17. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer.
Rudin CM; Reck M; Johnson ML; Blackhall F; Hann CL; Yang JC; Bailis JM; Bebb G; Goldrick A; Umejiego J; Paz-Ares L
J Hematol Oncol; 2023 Jun; 16(1):66. PubMed ID: 37355629
[TBL] [Abstract][Full Text] [Related]
18. Multifaceted Bioanalytical Methods for the Comprehensive Pharmacokinetic and Catabolic Assessment of MEDI3726, an Anti-Prostate-Specific Membrane Antigen Pyrrolobenzodiazepine Antibody-Drug Conjugate.
Huang Y; Del Nagro CJ; Balic K; Mylott WR; Ismaiel OA; Ma E; Faria M; Wheeler AM; Yuan M; Waldron MP; Peay MG; Cortes DF; Roskos L; Liang M; Rosenbaum AI
Anal Chem; 2020 Aug; 92(16):11135-11144. PubMed ID: 32459957
[TBL] [Abstract][Full Text] [Related]
19. Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates.
Caculitan NG; Dela Cruz Chuh J; Ma Y; Zhang D; Kozak KR; Liu Y; Pillow TH; Sadowsky J; Cheung TK; Phung Q; Haley B; Lee BC; Akita RW; Sliwkowski MX; Polson AG
Cancer Res; 2017 Dec; 77(24):7027-7037. PubMed ID: 29046337
[TBL] [Abstract][Full Text] [Related]
20. Rova-T enhances the anti-tumor activity of anti-PD1 in a murine model of small cell lung cancer with endogenous Dll3 expression.
Vitorino P; Chuang CH; Iannello A; Zhao X; Anderson W; Ferrando R; Zhang Z; Madhavan S; Karsunky H; Saunders LR
Transl Oncol; 2021 Jan; 14(1):100883. PubMed ID: 33074129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]